Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:AMYT

Amryt Pharma (AMYT) Stock Price, News & Analysis

Amryt Pharma logo

About Amryt Pharma Stock (NASDAQ:AMYT)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$14.63
$14.76
50-Day Range
$14.55
$14.70
52-Week Range
$6.41
$14.77
Volume
2.39 million shs
Average Volume
757,360 shs
Market Capitalization
$940.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

Remove Ads
Receive AMYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amryt Pharma and its competitors with MarketBeat's FREE daily newsletter.

AMYT Stock News Headlines

Alembic Pharmaceuticals Ltd.
AMYT Historical Data
Ex CIA predicts 40% “double crash” – April 11
The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… They’re studying something far more alien… Something you’ve never seen before…
Amryt Pharma Stock (NASDAQ:AMYT), Dividends
See More Headlines

AMYT Stock Analysis - Frequently Asked Questions

Amryt Pharma plc (NASDAQ:AMYT) posted its earnings results on Thursday, November, 5th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.73) by $0.66. The firm earned $49.33 million during the quarter. Amryt Pharma had a negative net margin of 8.19% and a positive trailing twelve-month return on equity of 1.70%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Amryt Pharma investors own include Alibaba Group (BABA), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD), Teladoc Health (TDOC), NIO (NIO), Tesla (TSLA).

Company Calendar

Last Earnings
11/05/2020
Today
3/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AMYT
Fax
N/A
Employees
2,020
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$1 million
Pretax Margin
-0.56%

Debt

Sales & Book Value

Annual Sales
$222.54 million
Cash Flow
$0.98 per share
Price / Cash Flow
14.98
Book Value
$5.58 per share
Price / Book
2.63

Miscellaneous

Free Float
60,343,000
Market Cap
$940.21 million
Optionable
Not Optionable
Beta
0.84
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:AMYT) was last updated on 3/14/2025 by MarketBeat.com Staff
From Our Partners